These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 31130710)

  • 1. Heterologous Immunity between Adenoviruses and Hepatitis C Virus (HCV): Recombinant Adenovirus Vaccine Vectors Containing Antigens from Unrelated Pathogens Induce Cross-Reactive Immunity Against HCV Antigens.
    Agrawal B; Gupta N; Vedi S; Singh S; Li W; Garg S; Li J; Kumar R
    Cells; 2019 May; 8(5):. PubMed ID: 31130710
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Heterologous Immunity between Adenoviruses and Hepatitis C Virus: A New Paradigm in HCV Immunity and Vaccines.
    Singh S; Vedi S; Samrat SK; Li W; Kumar R; Agrawal B
    PLoS One; 2016; 11(1):e0146404. PubMed ID: 26751211
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recombinant adenoviral vector expressing HCV NS4 induces protective immune responses in a mouse model of Vaccinia-HCV virus infection: a dose and route conundrum.
    Singh S; Vedi S; Li W; Samrat SK; Kumar R; Agrawal B
    Vaccine; 2014 May; 32(23):2712-21. PubMed ID: 24631092
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative Evaluation of the Vaccine Efficacies of Three Adenovirus-Based Vector Types in the Friend Retrovirus Infection Model.
    Hrycak CP; Windmann S; Bayer W
    J Virol; 2019 Nov; 93(21):. PubMed ID: 31375593
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A novel adenovirus type 6 (Ad6)-based hepatitis C virus vector that overcomes preexisting anti-ad5 immunity and induces potent and broad cellular immune responses in rhesus macaques.
    Capone S; Meola A; Ercole BB; Vitelli A; Pezzanera M; Ruggeri L; Davies ME; Tafi R; Santini C; Luzzago A; Fu TM; Bett A; Colloca S; Cortese R; Nicosia A; Folgori A
    J Virol; 2006 Feb; 80(4):1688-99. PubMed ID: 16439526
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Potent Anti-hepatitis C Virus (HCV) T Cell Immune Responses Induced in Mice Vaccinated with DNA-Launched RNA Replicons and Modified Vaccinia Virus Ankara-HCV.
    Marín MQ; Pérez P; Ljungberg K; Sorzano CÓS; Gómez CE; Liljeström P; Esteban M; García-Arriaza J
    J Virol; 2019 Apr; 93(7):. PubMed ID: 30674625
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of the E2 Hypervariable Region (HVR1) in the Immunogenicity of a Recombinant Hepatitis C Virus Vaccine.
    Law JLM; Logan M; Wong J; Kundu J; Hockman D; Landi A; Chen C; Crawford K; Wininger M; Johnson J; Mesa Prince C; Dudek E; Mehta N; Tyrrell DL; Houghton M
    J Virol; 2018 Jun; 92(11):. PubMed ID: 29540595
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of route of delivery on heterologous protection against HCV induced by an adenovirus vector carrying HCV structural genes.
    Guan J; Wen B; Deng Y; Zhang K; Chen H; Wu X; Ruan L; Tan W
    Virol J; 2011 Nov; 8():506. PubMed ID: 22054309
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Induction of antibodies against structural proteins of hepatitis C virus in mice using recombinant adenovirus.
    Makimura M; Miyake S; Akino N; Takamori K; Matsuura Y; Miyamura T; Saito I
    Vaccine; 1996 Jan; 14(1):28-36. PubMed ID: 8821646
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combined adenovirus vector and hepatitis C virus envelope protein prime-boost regimen elicits T cell and neutralizing antibody immune responses.
    Chmielewska AM; Naddeo M; Capone S; Ammendola V; Hu K; Meredith L; Verhoye L; Rychlowska M; Rappuoli R; Ulmer JB; Colloca S; Nicosia A; Cortese R; Leroux-Roels G; Balfe P; Bienkowska-Szewczyk K; Meuleman P; McKeating JA; Folgori A
    J Virol; 2014 May; 88(10):5502-10. PubMed ID: 24599994
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Unsolved Puzzles Surrounding HCV Immunity: Heterologous Immunity Adds Another Dimension.
    Agrawal B; Singh S; Gupta N; Li W; Vedi S; Kumar R
    Int J Mol Sci; 2017 Jul; 18(8):. PubMed ID: 28749434
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cross reactive cellular immune response to HCV genotype 1 and 4 antigens among genotype 4 exposed subjects.
    Galal IF; Zakaria Z; Allam WR; Mahmoud MA; Ezzat AR; Osman A; Waked I; Strickland GT; Abdelwahab SF
    PLoS One; 2014; 9(6):e101264. PubMed ID: 24979366
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Enhanced and sustained CD8+ T cell responses with an adenoviral vector-based hepatitis C virus vaccine encoding NS3 linked to the MHC class II chaperone protein invariant chain.
    Mikkelsen M; Holst PJ; Bukh J; Thomsen AR; Christensen JP
    J Immunol; 2011 Feb; 186(4):2355-64. PubMed ID: 21257961
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vaccination with an adenoviral vector encoding hepatitis C virus (HCV) NS3 protein protects against infection with HCV-recombinant vaccinia virus.
    Arribillaga L; de Cerio AL; Sarobe P; Casares N; Gorraiz M; Vales A; Bruna-Romero O; Borrás-Cuesta F; Paranhos-Baccala G; Prieto J; Ruiz J; Lasarte JJ
    Vaccine; 2002 Dec; 21(3-4):202-10. PubMed ID: 12450695
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adenoviruses vectored hepatitis C virus vaccine cocktails induce broadly specific immune responses against multi-genotypic HCV in mice.
    Luo S; Zhang P; Wang Y; Huang Y; Ma X; Deng Q; Zou P; Wang C; Zhang L; Li Y; Fu Y; Li T; Li C
    Biomed Pharmacother; 2024 Jan; 170():115901. PubMed ID: 38056238
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Enhancement of CD4 and CD8 immunity by anti-CD137 (4-1BB) monoclonal antibodies during hepatitis C vaccination with recombinant adenovirus.
    Arribillaga L; Sarobe P; Arina A; Gorraiz M; Borrás-Cuesta F; Ruiz J; Prieto J; Chen L; Melero I; Lasarte JJ
    Vaccine; 2005 May; 23(27):3493-9. PubMed ID: 15855007
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combination Adenovirus and Protein Vaccines Prevent Infection or Reduce Viral Burden after Heterologous Clade C Simian-Human Immunodeficiency Virus Mucosal Challenge.
    Malherbe DC; Mendy J; Vang L; Barnette PT; Reed J; Lakhashe SK; Owuor J; Gach JS; Legasse AW; Axthelm MK; LaBranche CC; Montefiori D; Forthal DN; Park B; Wilson JM; McLinden JH; Xiang J; Stapleton JT; Sacha JB; Haynes BF; Liao HX; Ruprecht RM; Smith J; Gurwith M; Haigwood NL; Alexander J
    J Virol; 2018 Jan; 92(2):. PubMed ID: 29093095
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of immunodominant hepatitis C virus (HCV)-specific cytotoxic T-cell epitopes by stimulation with endogenously synthesized HCV antigens.
    Urbani S; Uggeri J; Matsuura Y; Miyamura T; Penna A; Boni C; Ferrari C
    Hepatology; 2001 Jun; 33(6):1533-43. PubMed ID: 11391544
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immune responses against hepatitis C virus genotype 3a virus-like particles in mice: A novel VLP prime-adenovirus boost strategy.
    Kumar A; Das S; Mullick R; Lahiri P; Tatineni R; Goswami D; Bhat P; Torresi J; Gowans EJ; Karande AA; Das S
    Vaccine; 2016 Feb; 34(8):1115-25. PubMed ID: 26700891
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adenovirus type 4 and 7 vaccination or adenovirus type 4 respiratory infection elicits minimal cross-reactive antibody responses to nonhuman adenovirus vaccine vectors.
    Paris R; Kuschner RA; Binn L; Thomas SJ; Colloca S; Nicosia A; Cortese R; Bailer RT; Sullivan N; Koup RA
    Clin Vaccine Immunol; 2014 May; 21(5):783-6. PubMed ID: 24623627
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.